Neurogene Inc. develops genetic medicines for rare neurological diseases, with recurring updates centered on NGN-401, its investigational AAV9 gene therapy for Rett syndrome. Company news covers the EXACT™ transgene regulation technology, intracerebroventricular delivery for CNS-targeted gene therapy, clinical data from NGN-401 studies, and regulatory designations granted by U.S., European, and U.K. agencies.
Other recurring Neurogene developments include financial results, corporate presentations, scientific conference participation, board and executive appointments, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). The company also identifies NGN-101 as a conventional gene therapy development candidate for CLN5 Batten disease.
Neurogene Inc. (Nasdaq: NGNE) reported its first quarter 2024 financial results and highlighted recent corporate updates, focusing on the NGN-401 gene therapy trial for Rett syndrome. The company presented favorable safety data at the ASGCT Annual Meeting, received Australian HREC approval for the trial, and remains on track to provide interim efficacy data in Q4:24. Neurogene maintains a strong balance sheet with cash runway into 2H:26.
Neurogene Inc. presented favorable safety data from the Phase 1/2 trial of NGN-401 Gene Therapy for Rett Syndrome at the ASGCT Annual Meeting. The therapy was well-tolerated by the first three patients dosed, showing no signs of overexpression toxicity. The company remains on track to provide interim efficacy data in the fourth quarter of 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.